Vikasol tablets 15mg, No. 20

• Hemorrhagic syndrome associated with hypoprothrombinemia;

• hypovitaminosis K (including obstructive jaundice, hepatitis, liver cirrhosis, prolonged diarrhea);

• bleeding after wounds, trauma and surgery;

• as part of the complex therapy of dysfunctional uterine bleeding, menorrhagia;

• hemorrhagic disease of newborns (treatment and prevention);

• prophylactically during surgical interventions with possible severe parenchymal bleeding.

• Overdose of vitamin K antagonist drugs (warfarin, phenindione, acenocoumarol).

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Used internally.

The dose, method and scheme of administration are determined individually, depending on the indications, the age of the patient and the dosage form used.

Active ingredient: menadione sodium bisulfite - 15 mg

• Hypersensitivity to menadione,

• increased blood clotting (hypercoagulability),

• thromboembolism,

• hemolytic disease of the newborn (for parenteral use),

• pregnancy,

• lactation period (breastfeeding);

• children under 3 years old - depending on the dosage form.

With care: deficiency of glucose-6-phosphate dehydrogenase, liver failure.

Composition:

Active ingredient: menadione sodium bisulfite - 15 mg

Clinical and pharmacological group: Hemostatic drug. Vitamin K preparation

Pharmaco-therapeutic group: Vitamin K analog synthetic

pharmachologic effect

Antihemorrhagic agent. It is a synthetic analogue of vitamin K. It is a cofactor for the synthesis of prothrombin and other factors of blood coagulation (VII, IX, X) in the liver, contributes to the normalization of the blood coagulation process.

Pharmacokinetics

After oral administration, it is absorbed from the gastrointestinal tract. Plasma protein binding is reversible. It accumulates mainly in the liver, spleen, myocardium. It is converted into vitamin K2 in the body. The most intense transformation process occurs in the myocardium, skeletal muscles, somewhat weaker - in the kidneys.

Vitamin K metabolites (monosulfate, phosphate and diglucuronide-2-methyl-1.4-naphthoquinone) are excreted in the urine - up to 70%.

Indications of the active substances of the drug Vikasol

• Hemorrhagic syndrome associated with hypoprothrombinemia;

• hypovitaminosis K (including obstructive jaundice, hepatitis, liver cirrhosis, prolonged diarrhea);

• bleeding after wounds, trauma and surgery;

• as part of the complex therapy of dysfunctional uterine bleeding, menorrhagia;

• hemorrhagic disease of newborns (treatment and prevention);

• prophylactically during surgical interventions with possible severe parenchymal bleeding.

• Overdose of vitamin K antagonist drugs (warfarin, phenindione, acenocoumarol).

Dosage regimen

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Used internally.

The dose, method and scheme of administration are determined individually, depending on the indications, the age of the patient and the dosage form used.

Side effect

From the hematopoietic system: hemolytic anemia, hemolysis in newborns with congenital glucose-6-dehydrogenase deficiency.

From the respiratory system: bronchospasm.

From the nervous system: dizziness, change in taste.

From the side of the cardiovascular system: transient decrease in blood pressure, tachycardia, 'weak' pulse filling.

From the liver and biliary tract: jaundice (including kernicterus in newborns).

Allergic reactions: facial flushing, skin rash (including erythematous, urticaria), itching of the skin.

Others: hyperbilirubinemia, profuse sweat.

Local reactions: with intramuscular injection - pain and swelling at the injection site, skin lesions in the form of spots with repeated injections in the same place.

Contraindications for use

• Hypersensitivity to menadione,

• increased blood clotting (hypercoagulability),

• thromboembolism,

• hemolytic disease of the newborn (for parenteral use),

• pregnancy,

• lactation period (breastfeeding);

• children under 3 years old - depending on the dosage form.

With care: deficiency of glucose-6-phosphate dehydrogenase, liver failure.

Application during pregnancy and lactation

Contraindicated for use during pregnancy and lactation (breastfeeding). If necessary, use during lactation should decide on the termination of breastfeeding.

Application for violations of liver function

It should be used with caution in patients with hepatic impairment.

Application in children

It is possible to use in children according to indications, in doses and dosage forms recommended according to age. It is necessary to strictly follow the instructions in the instructions for menadione preparations on contraindications for the use of specific dosage forms of menadione in children of different ages.

special instructions

For diseases leading to impaired outflow of bile, parenteral administration of menadione is recommended. Menadione is ineffective in hemophilia, Werlhof's disease, and thrombocytopenic purpura (Wergolf's disease).

Menadion does not normalize the function of abnormal platelets. In patients with glucose-6-phosphate dehydrogenase deficiency, menadione can cause hemolysis.

Influence on the ability to drive vehicles and use mechanisms

During treatment, driving is not recommended, as well as engaging in other activities that require increased concentration of attention and speed of psychomotor reactions.

Drug interactions

Menadione reduces or blocks the anticoagulant effect of indirect anticoagulants - warfarin, phenindione and acenocoumarol. Does not affect the anticoagulant activity of direct anticoagulants (including heparin).

Antacids reduce the absorption of menadione due to the deposition of bile salts in the initial part of the small intestine.

Simultaneous use with broad-spectrum antibiotics, quinidine, quinine, salicylates in high doses, sulfonamides requires an increase in the dose of vitamin K (due to a violation of its synthesis by the intestinal microflora).

Cholestyramine, colestipol, mineral oils, sucralfate, dactinomycin reduce the absorption of vitamin K, which requires an increase in its dose.

With simultaneous use with drugs that cause hemolysis, the risk of side effects increases.